6533b820fe1ef96bd1279b23
RESEARCH PRODUCT
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Joaquin Martinez-lopezDiego AlignaniJesús Martín-sánchezNorma C. GutiérrezJuan Flores-monteroIbai GoicoecheaRafael RiosJoan BargayNoemi PuigLeire BurgosJuan José GarcésMaria-victoria MateosJuan José LahuertaJoan BladéMaría-belén VidrialesLourdes CordónLourdes CordónMaria-jose CalasanzIsabel KrsnikBruno PaivaMiguel-teodoro HernándezAlbert OriolSara RodriguezIdoia RodriguezMaria-teresa CedenaVicente FresquetLuis PalomeraSarai SarvideJ A Martinez-climentAmaia Vilas-zornozaAlberto OrfaoJavier De La RubiaJavier De La RubiaRafael Martínez-martínezRamón García-sanzDavid Lara-astiasoJosé-maría MoraledaJesús F. San MiguelLaura RosiñolJon CelayJosep SarráMaría-luisa Martín RamosDaniel Alamedasubject
OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myelomadescription
PETHEMA/GEM Cooperative Group.
year | journal | country | edition | language |
---|---|---|---|---|
2021-01-07 |